文献速递神经肿瘤功能神经外科

基于组织ACTH抗体检测引导的经蝶窦入路垂体腺瘤切除术治疗库欣病的长期结局

Long-term outcomes of tissue-based ACTH-antibody assay-guided transsphenoidal resection of pituitary adenomas in Cushing disease.
PubMed 文献 · J Neurosurg · 2017-10-13

该回顾性研究分析了2009至2014年接受经蝶窦入路手术、并由组织ACTH抗体检测引导的14例库欣病患者,共评估127份活检样本,平均随访3年。以290,000 pg/mg组织为阈值区分腺瘤与正常组织,灵敏度95.0%、特异度71.3%。85.7%患者获得长期缓解,缓解率高于历史对照(71.9%,p=0.0007)。

要点

  • 组织ACTH抗体检测区分腺瘤与正常组织的阈值为290,000 pg/mg组织,灵敏度95.0%、特异度71.3%。
  • 14例患者中85.7%获得长期疾病缓解,缓解率高于历史对照的71.9%(p=0.0007)。
  • 3例患者术前MRI与手术所见侧别不一致,提示单纯MRI可能无法实现最佳定位。

核心结论

  • 这些初步发现反映了基于组织的ACTH抗体引导检测在提高接受经蝶窦入路手术的库欣病患者治愈率方面具有前景。
  • 需要更大样本量、进一步改进检测判读以及更长随访时间的研究。

研究设计与样本

  • 回顾性研究,回顾病历并分析检测值、病理切片及MRI资料。
  • 纳入2009至2014年接受经蝶窦入路手术、随访至少1年并与内分泌科医生协作管理的库欣病患者。
  • 术中活检标本检测组织ACTH浓度,同时送冰冻切片病理分析。
  • 采用受试者工作特征(ROC)分析比较ACTH检测与病理评估,并与术前和术后MRI比较。

主要发现

  • 14例患者接受ACTH抗体检测引导的经蝶窦入路手术,评估127份活检样本,平均随访3年。
  • 区分腺瘤与正常组织的ACTH阈值为290,000 pg/mg组织,基于联合最大化的灵敏度95.0%和特异度71.3%。
  • 3例患者术前MRI与手术所见侧别不一致。
  • 85.7%的患者基于尿游离皮质醇水平、血浆皮质醇水平及长期糖皮质激素治疗获得长期疾病缓解。
  • 研究样本的缓解率在统计学上高于历史对照(71.9%;p=0.0007,Fisher精确检验);长期意外激素缺乏在研究患者(29%)与一项Meta分析(25%;p=0.7596,Fisher精确检验)之间统计学相似。

关键数值与推荐

  • 组织ACTH区分腺瘤与正常组织的阈值为290,000 pg/mg组织,灵敏度95.0%,特异度71.3%。
  • 长期疾病缓解率为85.7%,历史对照为71.9%(p=0.0007,Fisher精确检验)。
  • 长期意外激素缺乏在研究患者为29%,Meta分析为25%(p=0.7596,Fisher精确检验)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 这些为初步发现。
  • 需要更大样本量的研究。
  • 需要进一步改进检测判读。
  • 需要更长随访时间的研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE Cushing disease is caused by a pituitary micro- or macroadenoma that hypersecretes adrenocorticotropic hormone (ACTH), resulting in hypercortisolemia. For decades, transsphenoidal resection (TSR) has been an efficacious treatment but with certain limitations, namely precise tumor localization and complete excision. The authors evaluated the novel use of a double-antibody sandwich assay for the real-time quantitation of ACTH in resected pituitary specimens with the goals of augmenting pathological diagnosis and ultimately improving long-term patient outcome. METHODS This study involved a retrospective review of records and an analysis of assay values, pathology slides, and MRI studies of patients with Cushing disease who had undergone TSR in the period from 2009 to 2014 and had at least 1 year of follow-up in coordination with an endocrinologist. In the operating room, biopsy specimens from the patients had been analyzed for tissue ACTH concentration. Additional samples were simultaneously sent for frozen-section pathological analysis. The ACTH assay performance was compared against pathology assessments of surgical tumor samples using receiver operating characteristic (ROC) analysis and against pre- and postoperative MRI studies. RESULTS Fourteen patients underwent TSR with guidance by ACTH-antibody assay and pathological assessment of 127 biopsy samples and were followed up for an average of 3 years. The ACTH threshold for discriminating adenomatous from normal tissue was 290,000 pg/mg of tissue, based on jointly maximized sensitivity (95.0%) and specificity (71.3%). Lateralization discordance between preoperative MRI studies and surgical visualization was noted in 3 patients, confirming the impression that MRI alone may not achieve optimal localization. A majority of the patients (85.7%) attained long-term disease remission based on urinary free cortisol levels, plasma cortisol levels, and long-term corticosteroid therapy. Comparisons of patient-months of remission and treatment failure showed that the remission rate in the study sample statistically exceeds the rate in historical controls (71.9%; p = 0.0007, Fisher's exact test). Long-term unexpected hormonal deficiencies were statistically similar between study patients (29%) and those in a meta-analysis (25%; p = 0.7596, Fisher's exact test). CONCLUSIONS These preliminary findings reflect the promising potential of tissue-based ACTH-antibody-guided assay for improving the cure rates of Cushing disease patients undergoing TSR. Further studies with larger sample sizes, further refinements of assay interpretation, and longer-term follow-ups are needed.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Erfe JM, Perry A, McClaskey J, et al. Long-term outcomes of tissue-based ACTH-antibody assay-guided transsphenoidal resection of pituitary adenomas in Cushing disease. J Neurosurg. 2017. PMID: 29027854. doi:10.3171/2017.3.JNS162245

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。